Hypermethylated phenotypes

For more info about our services contact : help@bestpfe.com

Table of contents

INTRODUCTION
Chapter I. Gliomas: Epidemiology, Histo prognostic classification and Treatment options
I. Epidemiology
II. Histoprognostic classification of gliomas
III. Treatment options
Chapter II: Molecular classification of human gliomas
I. Genomic classification of gliomas
II. Epigenomic classification of gliomas
III. Transcriptomic classification of gliomas
Chapter III: Normal function of IDHs and IDH1/2 mutations in gliomas
I. Isoenzymes and roles in normal cell metabolism
II. IDH1 and IDH2 mutations in gliomas
OBJECTIVES
RESULTS
Publication n°1 « IDH mutations: genotype-phenotype correlation and
prognostic impact”
Publication n°2 “Prognostic impact of IDH1 SNP rs11554137 in
malignant gliomas”
Publication n°3 “Isocitrate dehydrogenase 1 mutation (IDH1 R132H)
increases U87 glioma cell sensitivity to radiation therapy in hypoxia”
DISCUSSION
I. Description of IDH1/IDH2 mutations in gliomas
II. Diagnostic value of IDH1/2 mutations and new methods for IDH status determination
III. Prognostic/ predictive value of IDH1/2 mutations
PERSPECTIVES
REFERENCES
ANNEXES
Article 4 “Chromosome 7p11.2 (EGFR) variation influences glioma risk.”
Article 5 “All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.”
Article 6 “IDH1 and IDH2 mutations in gliomas.”
Article 7 “COLD PCR HRM: a highly sensitive detection method for IDH1 mutations.”
Article 8 “IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.”